Epidemiologic  	Epidemiologic  	 JJ	B-NP
characteristics 	characteristics 	 NNS	I-NP
,  	,  	 ,	O
serotypes 	serotypes 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
antimicrobial  	antimicrobial  	 JJ	B-NP
susceptibilities  	susceptibilities  	 NN	I-NP
of  	of  	 IN	I-NP
invasive  	invasive  	 FW	I-NP
Streptococcus  	Streptococcus  	 FW	I-NP
pneumoniae  	pneumoniae  	 FW	I-NP
isolates  	isolates  	 FW	O
in  	in  	 IN	O
a  	a  	 DT	O
nationwide  	nationwide  	 JJ	O
surveillance  	surveillance  	 NN	B-NP
study  	study  	 NN	I-NP
in  	in  	 IN	O
Lebanon  	Lebanon  	 NNP	B-NP
Invasive  	Invasive  	 NNP	I-NP
pneumococcal  	pneumococcal  	 JJ	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
IPD 	IPD 	 NNP	B-NP
)  	)  	 -RRB-	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
Streptococcus  	Streptococcus  	 NNP	O
pneumonia  	pneumonia  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
major  	major  	 JJ	O
public  	public  	 JJ	B-NP
health  	health  	 NN	I-NP
problem  	problem  	 NN	I-NP
worldwide  	worldwide  	 NN	O
for  	for  	 IN	O
all  	all  	 DT	O
age  	age  	 NN	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
in  	in  	 IN	O
Lebanon 	Lebanon 	 NNP	B-NP
.  	.  	 .	O
Prevention  	Prevention  	 NN	O
through  	through  	 IN	O
vaccination  	vaccination  	 NN	O
remains  	remains  	 VBZ	O
the  	the  	 DT	O
most  	most  	 RBS	O
valuable  	valuable  	 JJ	O
tool  	tool  	 NN	O
to  	to  	 TO	O
decrease  	decrease  	 VB	O
the  	the  	 DT	O
burden  	burden  	 NN	O
of  	of  	 IN	O
disease 	disease 	 NN	O
.  	.  	 .	O
Pneumococcal  	Pneumococcal  	 JJ	B-NP
conjugate  	conjugate  	 JJ	I-NP
vaccine  	vaccine  	 NN	I-NP
7  	7  	 CD	I-NP
( 	( 	 -LRB-	O
PCV7 	PCV7 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
marketed  	marketed  	 VBD	O
internationally  	internationally  	 RB	O
including  	including  	 VBG	O
in  	in  	 IN	O
the  	the  	 DT	O
Middle  	Middle  	 NNP	O
East  	East  	 NNP	O
and  	and  	 CC	O
North  	North  	 NNP	O
Africa  	Africa  	 NNP	O
region  	region  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
IPD 	IPD 	 NNP	B-NP
,  	,  	 ,	O
was  	was  	 VBD	O
introduced  	introduced  	 VBN	O
in  	in  	 IN	O
Lebanon  	Lebanon  	 NNP	B-NP
in  	in  	 IN	O
2006 	2006 	 CD	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
PCV10  	PCV10  	 NNP	B-NP
and  	and  	 CC	O
PCV13  	PCV13  	 CD	B-NP
in  	in  	 IN	O
2010 	2010 	 CD	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
none  	none  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
is  	is  	 VBZ	O
currently  	currently  	 RB	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Extended  	Extended  	 JJ	B-NP
Program  	Program  	 NN	I-NP
of  	of  	 IN	I-NP
Immunization  	Immunization  	 NNP	I-NP
schedule  	schedule  	 NN	I-NP
and  	and  	 CC	O
published  	published  	 VBN	O
data  	data  	 NNS	O
on  	on  	 IN	O
IPD  	IPD  	 NNP	B-NP
incidence 	incidence 	 NN	I-NP
,  	,  	 ,	O
pneumococcal  	pneumococcal  	 JJ	B-NP
serotypes  	serotypes  	 NN	I-NP
and  	and  	 CC	O
vaccine  	vaccine  	 NN	B-NP
coverage  	coverage  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
region  	region  	 NN	O
are  	are  	 VBP	O
lacking 	lacking 	 VBG	O
.  	.  	 .	O
The  	The  	 DT	O
Lebanese  	Lebanese  	 JJ	O
Inter-Hospital  	Inter-Hospital  	 JJ	B-NP
Pneumococcal  	Pneumococcal  	 NNP	I-NP
Surveillance  	Surveillance  	 NNP	I-NP
Program  	Program  	 NNP	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
surveillance  	surveillance  	 NN	B-NP
system  	system  	 NN	I-NP
set  	set  	 VBN	O
up  	up  	 RP	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
burden  	burden  	 NN	O
of  	of  	 IN	O
IPD  	IPD  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
prevalent  	prevalent  	 JJ	O
serotypes  	serotypes  	 JJ	B-NP
responsible 	responsible 	 JJ	I-NP
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
prospective  	prospective  	 JJ	O
6-year  	6-year  	 CD	O
study  	study  	 NN	O
carried  	carried  	 VBD	O
out  	out  	 RP	O
in  	in  	 IN	O
78  	78  	 CD	O
hospitals  	hospitals  	 NNS	O
throughout  	throughout  	 IN	O
Lebanon  	Lebanon  	 NNP	B-NP
was  	was  	 VBD	O
to  	to  	 TO	O
obtain  	obtain  	 VB	O
such  	such  	 JJ	O
data  	data  	 NNS	O
to  	to  	 TO	O
help  	help  	 VB	O
health  	health  	 NN	B-NP
authorities  	authorities  	 NNS	I-NP
make  	make  	 VBP	O
informed  	informed  	 VBN	B-NP
decisions  	decisions  	 NNS	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
implementation  	implementation  	 NN	B-NP
of  	of  	 IN	I-NP
pneumococcal  	pneumococcal  	 JJ	I-NP
vaccination  	vaccination  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
national  	national  	 JJ	O
level 	level 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
257  	257  	 CD	O
isolates  	isolates  	 NN	O
of  	of  	 IN	O
culture-confirmed  	culture-confirmed  	 NNP	O
Streptococcus  	Streptococcus  	 NNP	B-NP
pneumoniae  	pneumoniae  	 NN	I-NP
were  	were  	 VBD	O
evaluated 	evaluated 	 VBN	O
.  	.  	 .	O
Considering  	Considering  	 VBG	O
all  	all  	 DT	O
age  	age  	 NN	B-NP
groups 	groups 	 NNS	I-NP
,  	,  	 ,	O
vaccine  	vaccine  	 NN	B-NP
coverage  	coverage  	 NN	I-NP
was  	was  	 VBD	O
41.4 	41.4 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
53.9 	53.9 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
67.2 	67.2 	 CD	O
%  	%  	 NN	O
for  	for  	 IN	O
PCV7 	PCV7 	 NNP	B-NP
,  	,  	 ,	O
PCV10 	PCV10 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
PCV13  	PCV13  	 CD	B-NP
serotypes 	serotypes 	 NN	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
;  	;  	 :	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
< 	< 	 SYM	O
2 	2 	 CD	O
,  	,  	 ,	O
2-5 	2-5 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
> 	> 	 CD	O
60  	60  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
,  	,  	 ,	O
PCV7  	PCV7  	 CD	B-NP
coverage  	coverage  	 NN	I-NP
was  	was  	 VBD	O
50 	50 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
51 	51 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
35 	35 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
;  	;  	 :	O
PCV10  	PCV10  	 CD	B-NP
coverage  	coverage  	 NN	I-NP
was  	was  	 VBD	O
53 	53 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
74 	74 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
45 	45 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
;  	;  	 :	O
and  	and  	 CC	O
PCV13  	PCV13  	 CD	B-NP
coverage  	coverage  	 NN	I-NP
was  	was  	 VBD	O
63 	63 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
80 	80 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
68 	68 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
17.4 	17.4 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
isolates  	isolates  	 NN	O
were  	were  	 VBD	O
penicillin-G  	penicillin-G  	 JJ	B-NP
non-susceptible  	non-susceptible  	 JJ	I-NP
using  	using  	 VBG	O
the  	the  	 DT	O
latest  	latest  	 JJS	O
established  	established  	 JJ	O
breakpoints  	breakpoints  	 NN	B-NP
and  	and  	 CC	O
mortality  	mortality  	 NN	O
occurred  	occurred  	 VBD	O
in  	in  	 IN	O
23.5 	23.5 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
non-susceptible  	non-susceptible  	 JJ	B-NP
isolates 	isolates 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
10.9 	10.9 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
isolates  	isolates  	 NN	O
were  	were  	 VBD	O
multi-drug-resistant 	multi-drug-resistant 	 JJ	B-NP
.  	.  	 .	O
The  	The  	 DT	O
highest  	highest  	 JJS	O
mortality  	mortality  	 NN	B-NP
rates  	rates  	 NNS	I-NP
were  	were  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
eldest  	eldest  	 NN	O
( 	( 	 -LRB-	O
> 	> 	 CD	O
60  	60  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
youngest  	youngest  	 JJS	O
(  	(  	 -LRB-	O
< 	< 	 SYM	O
2  	2  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age 	age 	 NN	O
)  	)  	 -RRB-	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
prevalent  	prevalent  	 JJ	O
invasive  	invasive  	 NNS	O
serotypes  	serotypes  	 VBP	O
identified  	identified  	 VBN	O
were  	were  	 VBD	O
those  	those  	 DT	O
found  	found  	 VBN	O
in  	in  	 IN	O
currently  	currently  	 RB	O
available  	available  	 JJ	O
pneumococcal  	pneumococcal  	 JJ	O
conjugate  	conjugate  	 JJ	O
vaccines 	vaccines 	 NNS	O
,  	,  	 ,	O
emphasizing  	emphasizing  	 VBG	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
implementing  	implementing  	 VBG	O
the  	the  	 DT	O
vaccine  	vaccine  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
routine  	routine  	 JJ	B-NP
immunization  	immunization  	 JJ	I-NP
schedule  	schedule  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
national  	national  	 JJ	O
level 	level 	 NN	O
.  	.  	 .	O
Continuation  	Continuation  	 NN	B-NP
of  	of  	 IN	O
current  	current  	 JJ	O
surveillance  	surveillance  	 NN	B-NP
practices  	practices  	 NNS	I-NP
will  	will  	 MD	O
help  	help  	 VB	O
assess  	assess  	 VB	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
vaccine  	vaccine  	 NN	B-NP
implementation  	implementation  	 NN	I-NP
on  	on  	 IN	O
IPD  	IPD  	 NNP	B-NP
epidemiology 	epidemiology 	 NN	I-NP
,  	,  	 ,	O
serotype  	serotype  	 JJ	B-NP
distribution  	distribution  	 NN	I-NP
and  	and  	 CC	O
antibiotic  	antibiotic  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
patterns 	patterns 	 NNS	I-NP
.  	.  	 .	O
